Neurocrine Biosciences Inc.

Neuroscience-focused company with Ingrezza (valbenazine) as the leading therapy for tardive dyskinesia and a growing pipeline in movement disorders, neuropsychiatry, and neuroendocrine diseases including congenital adrenal hyperplasia (crinecerfont).